| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
| ln Vitro |
At a Ki value of 7.4 μM, A-3 hydrochloride competitively inhibits MLC kinase in comparison to ATP. A-3 exhibits competitive inhibition against cAMP-dependent protein kinase, cGMP-dependent protein kinase, protein kinase C, casein kinase I, and casein kinase II, with corresponding Ki values of 4.3 μM, 3.8 μM, and 47 in relation to ATP. consist of μM, 80 μM, and 5.1 μM[1].
|
|---|---|
| References |
| Molecular Formula |
C12H13N2O2SCL.HCL
|
|---|---|
| Molecular Weight |
321.22276
|
| Exact Mass |
320.015
|
| CAS # |
78957-85-4
|
| PubChem CID |
9861903
|
| Appearance |
Light yellow to light brown solid powder
|
| Melting Point |
173-176ºC
|
| LogP |
4.704
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
19
|
| Complexity |
369
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
VWAGIWCLJAQLAL-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C12H13ClN2O2S.ClH/c13-11-5-1-4-10-9(11)3-2-6-12(10)18(16,17)15-8-7-14;/h1-6,15H,7-8,14H2;1H
|
| Chemical Name |
N-(2-aminoethyl)-5-chloronaphthalene-1-sulfonamide;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~389.14 mM)
H2O : ~50 mg/mL (~155.66 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (6.48 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (6.48 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1131 mL | 15.5657 mL | 31.1313 mL | |
| 5 mM | 0.6226 mL | 3.1131 mL | 6.2263 mL | |
| 10 mM | 0.3113 mL | 1.5566 mL | 3.1131 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT00976209 | COMPLETEDWITH RESULTS | Drug: Phenylephrine Hydrochloride (HCl) Extended Release (ER) Tablets 30 mg Drug: Phenylephrine Hydrochloride (HCl) Immediate Release (IR) tablets, 10 mg |
Seasonal Allergic Rhinitis Vasomotor Rhinitis |
Bayer | 2009-08 | Phase 3 |
| NCT06218784 | RECRUITING | Drug: iN1011-N17 HCl Suspension (Part 1)
Drug: iN1011-N17 HCl Capsule (Part 1) Drug: Placebo Capsule (Part 1) |
Chronic Pain Dorsal Root Ganglion Nav 1.7 Neuropathic Pain |
iN Therapeutics Co., Ltd. | 2022-11-11 | Phase 1 |
| NCT02097056 | COMPLETEDWITH RESULTS | Drug: Donepezil HCL | Alzheimer's Disease | Eisai Korea Inc. | 2014-02 | Phase 4 |
| NCT02473783 | COMPLETEDWITH RESULTS | Drug: Sertraline HCl Other: I-123-ADAM SPECT |
Major Depressive Disorder | Tri-Service General Hospital | 2011-10 | Phase 2 |
| NCT03459534 | RECRUITING | Drug: Radotinib HCl | CML - Philadelphia Chromosome CML, Chronic Phase CML, Refractory Chronic Myeloid Leukemia, Chronic Phase |
Il-Yang Pharm. Co., Ltd. | 2018-06-25 | Phase 3 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
